| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 7645566 | Revue Francophone des Laboratoires | 2017 | 6 Pages |
Abstract
The therapeutic care of patients with chronic hepatitis C knew an upheaval for these last 5 years with the advent of direct antiviral agents (DAAs). Interferon-free regimens with combinations of DAAs allow to achieve rates of sustained virological response, and thus eradication of HCV, higher than 90%, whatever the profile of the patient, with an excellent tolerance and short durations of treatment ranging between 8 and 24 weeks. After 3 years of DAAs use in France, the new antiviral strategies raise several questions as the treatment access and screening of patients, the contribution of « real life studies », the viral resistances, and the management of patients having an advanced liver disease.
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Analytical Chemistry
Authors
Lawrence Serfaty,